Key result
Aspirin carries a ~44% higher risk of post-orthopaedic VTE compared to LMWH.
Why the study?
The efficiency and safety of aspirin compared with low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery patients needed evaluation.
Does aspirin compared with low-molecular-weight heparin effectively and safely prevent venous thromboembolism in adult patients undergoing orthopaedic surgery?
Meta-Analysis (n=23,327)
RCTs included
Yes
Does aspirin compared with low-molecular-weight heparin effectively and safely prevent venous thromboembolism in adult patients undergoing orthopaedic surgery?
Despite comparable safety profiles regarding bleeding and wound complications, low-molecular-weight heparin remains significantly more effective than aspirin at preventing venous thromboembolism (particularly DVT) after major orthopaedic surgery.
Answers are grounded in this paper and cite their sources.
LMWH should be preferred over aspirin for post-orthopaedic VTE prophylaxis; challenges recent large RCTs suggesting equivalence.
The article aimed to compare the efficiency and safety of aspirin with low-molecular-weight heparin (LMWH) for thromboprophylaxis in orthopaedic surgery patients. According to the inclusion and exclusion criteria, PubMed, Embase and Cochrane Library database were searched for studies comparing aspirin and LMWH in venous thromboembolism (VTE) prophylaxis until 25 April 2023. The outcome measures included deep venous thrombosis(DVT)/Pulmonary embolism(PE) events, major bleeding events, wound complications, wound infection and death. Six studies met the requirements of our meta-analysis, including 12 470 patients in the aspirin group and 10 857 patients in the LMWH group. The meta-analysis showed that results showed that LMWH was superior to aspirin in preventing VTE events (odds ratio (OR) 1.44, 95% CI 1.24-1.68, P < 0.00001), whereas there was no significant difference between them in bleeding events (OR 0.95, 95% CI 0.86-1.05, P = 0.33), wound complication (OR 0.58, 95% CI 0.28-1.17, P = 0.13), wound infection (OR 1.12, 95% CI 0.86-1.47, P = 0.39) and mortality (OR 1.04, 95% CI 0.70-1.55, P = 0.83). In addition, subgroup analysis showed that compared with aspirin, LMWH was more likely to reduce the incidence of DVT events in orthopaedic surgery patients (OR 1.59, 95% CI 1.33-1.91, P < 0.00001), whereas there was no advantage in reducing the incidence of PE events (OR 1.22, 95% CI 0.62-2.40, P = 0.56). Despite the similar safety profiles, this meta-analysis showed that LMWH was significantly superior to aspirin in thromboprophylaxis after orthopaedic surgery. LMWH was still the first-line drug for thrombosis prevention in patients who underwent major orthopaedic surgeries.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) conducted a meta-analysis in Venous thromboembolism prophylaxis after orthopaedic surgery (n=23,327). Aspirin vs. Low-molecular-weight heparin (enoxaparin or dalteparin, 2500 U to 5000 U once daily or 30-40 mg once/twice daily) was evaluated on Venous thromboembolism (VTE) events (deep venous thrombosis or pulmonary embolism) (OR 1.44, 95% CI 1.24-1.68, p=<0.00001). Aspirin was associated with a higher risk of venous thromboembolism compared to low-molecular-weight heparin after orthopaedic surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: